Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P60201
UPID:
MYPR_HUMAN
Alternative names:
Lipophilin
Alternative UPACC:
P60201; P04400; P06905; Q502Y1; Q6FHZ6
Background:
Myelin proteolipid protein, also known as Lipophilin, is the central nervous system's major myelin protein, crucial for the formation or maintenance of myelin's multilamellar structure. Its pivotal role ensures proper nerve fiber insulation and signal transmission.
Therapeutic significance:
Linked to disorders such as Leukodystrophy, hypomyelinating, 1, and Spastic paraplegia 2, X-linked, Myelin proteolipid protein's dysfunction underscores its therapeutic potential. Targeting its pathway could lead to breakthroughs in treating these debilitating neurological conditions.